OD004

OD004 is an experimental therapeutic candidate being developed by Ocular Discovery, a portfolio company of the Drug Rediscovery Group, for the treatment of Ocular Graft-versus-Host Disease (oGvHD). Ocular GvHD is a serious complication following allogeneic hematopoietic stem cell transplantation, characterized by inflammation and damage to the ocular surface and lacrimal glands. OD004 is part of a pipeline of ophthalmic drugs identified through a rediscovery platform, which focuses on repurposing or reformulating existing compounds for new ocular indications. While specific details regarding its molecular target and chemical modality are not publicly disclosed by the developer, the candidate is currently in the early stages of development aimed at addressing the unmet medical needs of patients with inflammatory ocular surface diseases.